Year 2021 / Volume 28 / Supplement 1

Article Osteoarthritis Monographic

Epidemiology, clinical impact and therapeutic objectives in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 4-10 / DOI: 10.20986/resed.2021.3874/2020

Víctor Mayoral


ABSTRACT

Osteoarthritis is one of the main health problems in all countries, most prevalent in developed countries, probably due to factors such as increased longevity, a sedentary lifestyle and obesity. Health statistics show a continued growth in its overall impact and importance on disability.
The objective is to analyze and synthesize the health problem posed by osteoarthritis, providing epidemiological data on prevalence, clinical impact, loss of quality of life and costs it causes. Those therapeutic objectives that are clinically relevant, will be shown, both those preventive and modifiable as well as the cofactors that modify the degree of response to them.
Systematic review of the literature of the last 10 years in the Pubmed database for terms "Mesh" related to epidemiology, prevention, treatment, and patient reported outcomes for knee and hip osteoarthritis.
We have found great variability in reported epidemiological results, a consequence of the different inclusion criteria and methodology of studies, showing prevalence of 83% in Magnetic Resonance studies with asymptomatic patients up to 3.8% of symptomatic knee osteoarthritis in adult population studies. Age, female sex, ethnicity and obesity seem like the most important factors related to the disease. Other factors such as genetics, biomechanics resulting from sports and occupational injuries, hormonal, metabolic syndrome and sedentary lifestyles have shown a clear association with the disease. The direct and indirect cost of osteoarthritis represents between 0.5 and 1% of GDP, according to countries. The review of therapeutic goals shows that patients perceive as minimally relevant changes those therapies that achieve a decrease of 2 points or 33 % on the VAS Analypain scale, but these cut-off points will depend on the affected joint and the severity of the initial pain. The chronology and persistence of pain despite treatments that may correct the mechanical component such as joint replacement seems related to extraarticular factors such as psychological ones, non-nociceptive pain phenotype, other diseases that cause local or diffuse pain with different degrees of sensitization as well as sociocultural factors.
The incidence and prevalence of symptomatic osteoarthritis is high. We know those modifiable factors with which we can help patients and people prevent it or minimize its consequences on disability. Therapeutic efforts should be aimed at using resources that have shown real clinically relevant changes. We must also address those non-mechanical cofactors that promote the persistence of pain and enhance those therapeutic strategies that are based on a multidisciplinary approach.



RESUMEN

La artrosis es uno de los principales problemas de salud en todos los países, más prevalente en los países desarrollados probablemente debido a factores como el aumento de la longevidad, el sedentarismo y la obesidad. Las estadísticas de salud muestran un continuo crecimiento de su incidencia e importancia global sobre la discapacidad.
El objetivo es analizar y sintetizar el problema de salud que representa la artrosis, aportando datos epidemiológicos de prevalencia, repercusión clínica, pérdida de calidad de vida y costes que ocasiona. Se muestran los objetivos terapéuticos que son clínicamente relevantes, tanto aquellos preventivos o modificables como los cofactores que modifican el grado de respuesta a los mismos.
Se trata de una revisión sistemática de la literatura de los últimos 10 años en la base de datos PubMed para términos “Mesh” relacionados con epidemiología, prevención, tratamiento y resultados informados por el paciente para artrosis de rodilla y cadera.
Hemos encontrado una gran variabilidad en los resultados epidemiológicos comunicados, consecuencia de los diferentes criterios de inclusión y metodología de los estudios, mostrando prevalencias del 83 % en estudios con resonancia magnética en pacientes asintomáticos hasta el 3,8 % de artrosis sintomática de rodilla en estudios poblacionales en adultos. La edad, el sexo femenino, la etnia y la obesidad parecen ser los factores más importantes relacionados con la enfermedad. Otros factores como los genéticos, biomecánicos (consecuencia de lesiones deportivas y ocupacionales), hormonales, el síndrome metabólico y el sedentarismo han mostrado una clara asociación con la enfermedad. El coste directo e indirecto de la artrosis representa entre el 0,5 y el 1 % del PIB, según países. La revisión de los objetivos terapéuticos muestra que los pacientes perciben como cambios mínimamente relevantes aquellas terapias que consiguen una disminución de 2 puntos en la escala de dolor EVA o un 33 %, pero estos puntos de corte van a depender de la articulación afectada y del grado de dolor inicial. La cronificación y persistencia del dolor, a pesar de tratamientos que corrigen el componente mecánico como el protésico articular, parecen relacionados con factores extrarticulares como los psicológicos, fenotipos de dolor no nociceptivos, otras enfermedades que provocan dolor local o difuso con diferentes grados de sensibilización y otros factores socioculturales.
La incidencia y prevalencia de la artrosis sintomática es alta. Conocemos aquellos factores modificables con los que podemos ayudar a los pacientes y población a prevenirla o minimizar sus consecuencias sobre la discapacidad. Los esfuerzos terapéuticos deben ir encaminados a utilizar recursos que hayan mostrado cambios clínicamente. Debemos también incidir en aquellos cofactores no mecánicos que favorecen la persistencia del dolor y potenciar las estrategias terapéuticas que se apoyan en un enfoque multidisciplinar.





Complete Article

Nuevo comentario

Security code:
CAPTCHA code image
Speak the codeChange the code
 

Comentarios

No comments in this article

Bibliografía

1. Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: Influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659-64. DOI: 10.1136/annrheumdis-2013-203355.
2. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59. DOI: 10.1016/S0140-6736(17)32154-2.
3. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA - J Am Med Assoc. 2020;323(9):863-84. DOI: 10.1001/jama.2020.0734.
4. Garriga XM. Definición, etiopatogenia, clasificación y formas de presentación. Aten Primaria. 2014;46(SUPPL 1):3-10. DOI: 10.1016/S0212-6567(14)70037-X.
5. Lespasio MJ, Sultan AA, Piuzzi NS, Khlopas A, Husni ME, Muschler GF, et al. Hip Osteoarthritis: A Primer. Perm J. 2018;22:89-94. DOI: 10.7812/TPP/17-084.
6. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. DOI: 10.1136/ard.16.4.494.
7. Pereira D, Severo M, Santos RA, Barros H, Branco J, Lucas R, et al. Knee and hip radiographic osteoarthritis features: differences on pain, function and quality of life. Clin Rheumatol. 2016;35(6):1555-64. DOI: 10.1007/s10067-015-3087-7.
8. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. DOI: 10.1002/acr.24131.
9. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30. DOI: 10.1136/annrheumdis-2013-204763.
10. Carmona L, Ballina J, Gabriel R, Laffon A. The burden of musculoskeletal diseases in the general population of Spain: Results from a national survey. Ann Rheum Dis. 2001;60(11):1040-5. DOI: 10.1136/ard.60.11.1040.
11. Busija L, Bridgett L, Williams SRM, Osborne RH, Buchbinder R, March L, et al. Osteoarthritis. Best Pract Res Clin Rheumatol. 2010;24(6):757-68. DOI: 10.1016/j.berh.2010.11.001.
12. Murphy L, Helmick CG. The Impact of Osteoarthritis in the United States. Orthop Nurs. 2012;31(2):85-91. DOI: 10.1097/NOR.0b013e31824fcd42.
13. O’Neill TW, McCabe PS, McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Pract Res Clin Rheumatol [Internet]. 2018;32(2):312-26. DOI: 10.1016/j.berh.2018.10.007.
14. Kremers HM, Larson DR, Crowson CS, Kremers WK, Washington RE, Steiner CA, et al. Prevalence of total hip and knee replacement in the United States. J Bone Jt Surg - Am Vol. 2014;97(17):1386-97. DOI: 10.2106/JBJS.N.01141.
15. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: The minimal clinically important improvement. Ann Rheum Dis. 2005;64(1):29-33. DOI: 10.1136/ard.2004.022905.
16. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283-91. DOI: 10.1016/j.ejpain.2003.09.004.
17. Zengini E, Finan C, Wilkinson JM. The Genetic Epidemiological Landscape of Hip and Knee Osteoarthritis: Where Are We Now and Where Are We Going? J Rheumatol. 2016;43(2):260-6. DOI: 10.3899/jrheum.150710.
18. Godziuk K, Prado CM, Woodhouse LJ, Forhan M. The impact of sarcopenic obesity on knee and hip osteoarthritis: a scoping review. BMC Musculoskelet Disord. 2018;19(1):271. DOI: 10.1186/s12891-018-2175-7.
19. Courties A, Berenbaum F, Sellam J. The Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated Osteoarthritis. Jt Bone Spine [Internet]. 2019;86(6):725-30. DOI: 10.1016/j.jbspin.2018.12.005.
20. Kraus VB, Sprow K, Powell KE, Buchner D, Bloodgood B, Piercy K, et al. Effects of Physical Activity in Knee and Hip Osteoarthritis: A Systematic Umbrella Review. Med Sci Sports Exerc. 2019;51(6):1324-39. DOI: 10.1249/MSS.0000000000001944.
21. Hardcastle SA, Dieppe P, Gregson CL, Davey Smith G, Tobias JH. Osteoarthritis and bone mineral density: are strong bones bad for joints? Bonekey Rep [Internet]. 2015;4(January):1-8. DOI: 10.1038/bonekey.2014.119.
22. Molloy MG, Molloy CB. Contact sport and osteoarthritis. Br J Sports Med. 2011;45(4):275-7. DOI: 10.1136/bjsm.2011.083956.
23. Fransen M, Agaliotis M, Bridgett L, Mackey MG. Hip and knee pain: role of occupational factors. Best Pract Res Clin Rheumatol. 2011;25(1):81-101. DOI: 10.1016/j.berh.2011.01.012.
24. Ten Klooster PM, De Graaf N, Vonkeman HE. Association between pain phenotype and disease activity in rheumatoid arthritis patients: A non-interventional, longitudinal cohort study. Arthritis Res Ther. 2019;21(1):1-10. DOI: 10.1186/s13075-019-2042-4.
25. Lee CY, Bingham CO, Edwards RR, Marder W, Phillips K, Bolster MB, et al. Pain Sensitization is Associated with Disease Activity in Rheumatoid Arthritis Patients: A Cross-Sectional Study. Arthritis Care Res (Hoboken). 2018;70(2):197-204. DOI: 10.1002/acr.23266.
26. Orhan C, Van Looveren E, Cagnie B, Mukhtar NB, Lenoir D, Meeus M. Are pain beliefs, cognitions, and behaviors influenced by race, ethnicity, and culture in patients with chronic musculoskeletal pain: A systematic review. Pain Physician. 2018;21(6):541-58.
27. Geenen R, Overman CL, Christensen R, Åsenlöf P, Capela S, Huisinga KL, et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. DOI: 10.1136/annrheumdis-2017-212662.
28. Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Non-inflammatory Causes of Pain in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep. 2016;18(6):30. DOI: 10.1007/s11926-016-0581-0.
29. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev. 2011;11(2):123-31. DOI: 10.1016/j.autrev.2011.09.001.
30. Guermazi A, Niu J, Hayashi D, Roemer FW, Englund M, Neogi T, et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: Population based observational study (Framingham Osteoarthritis Study). BMJ. 2012;345:e5339. DOI: 10.1136/bmj.e5339.
31. Kjellberg J, Kehlet H. A nationwide analysis of socioeconomic outcomes after hip and knee replacement. Dan Med J. 2016g;63(8):A5257.

Artículos relacionados

Effects of hydrotherapy on pain in osteoarthritis and fibromyalgia: a narrative review

Rev. Soc. Esp. Dolor. 2022; 29(2): 78-87 / DOI: 10.20986/resed.2022.3955/2021

Genicular nerve radiofrequency in osteoarthritis-related chronic knee pain

Rev. Soc. Esp. Dolor. 2021; 28(3): 154-168 / DOI: 10.20986/resed.2021.3900/2021

Interventional management of osteoarthritic pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 85-90 / DOI: 10.20986/resed.2021.3853/2020

Platelet rich plasma and intra-articular mesenchymal stem cells in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 80-84 / DOI: 10.20986/resed.2021.3858/2020

Intra-articular botulinum toxin and ozone in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 73-79 / DOI: 10.20986/resed.2021.3857/2020

Infiltrations of steroids and hyaluronic acid in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 64-72 / DOI: 10.20986/resed.2021.3854/2020

New pharmacological targets for osteoarthritis induced pain

Rev. Soc. Esp. Dolor. 2021; 28(13): 57-63 / DOI: 10.20986/resed.2021.3863/2020

Opioids in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 49-56 / DOI: 10.20986/resed.2021.3855/2020

News in the clinical practice guidelines regarding the treatment of the hip, knee and hands osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 38-42 / DOI: 10.20986/resed.2021.3870/2020

Central sensitization in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 31-37 / DOI: 10.20986/resed.2021.3876/2020

Experimental models for pain evaluation in osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 18-30 / DOI: 10.20986/resed.2021.3872/2020

Ethiopathogenic mechanism of osteoarthritis

Rev. Soc. Esp. Dolor. 2021; 28(13): 11-17 / DOI: 10.20986/resed.2021.3851/2020

Osteoarthritis and pain: the complexity and impact of a symptom

Rev. Soc. Esp. Dolor. 2021; 28(13): 1-3 / DOI: 10.20986/resed.2021.3886/2021

Effectiveness and current recommendation of manual therapy on hip osteoarthritis. An overview

Rev. Soc. Esp. Dolor. 2020; 27(6): 375-391 / DOI: 10.20986/resed.2021.3835/2020

Opioid misuse in patients with cancer pain: an integrative systematic review of the literature

Rev. Soc. Esp. Dolor. 2020; 27(5): 306-315 / DOI: 10.20986/resed.2020.3801/2020

Conventional radiofrequency for genicular nerves in treatment of knee osteoarthritis

Rev. Soc. Esp. Dolor. 2020; 27(1): 59-60 / DOI: 10.20986/resed.2016.3515/2016

Chrono study: prevalence of breakthrough pain among patients with non-cancer chronic pain in Andalusia, Spain

Rev Soc Esp Dolor 2018; 25(4): 214-221 / DOI: 10.20986/resed.2017.3626/2017

Instrucciones para citar

Mayoral V. Epidemiology, clinical impact and therapeutic objectives in osteoarthritis. Rev Soc Esp Dolor 2021; 28(13): 4-10 / DOI: 1020986/resed20213874/2020


Descargar a un gestores de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica

Este artículo ha sido visitado 23109 veces.
Este artículo ha sido descargado 10 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Aceptado: 18/01/2021

Publicado: 03/02/2021


Compartir

Este artículo aun no tiene valoraciones.
Reader rating:
Rate this article:
© 2024 Revista de la Sociedad Española del Dolor
ISSN: 1134-8046   e-ISSN: 2254-6189

      Indexada en: